| HOME >> BIOLOGY >> TECHNOLOGY |
BASINGSTOKE, England, April 24 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP) (NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that Michael Rosenblatt M.D. will join the Board as a Non-Executive Director with immediate effect.
Dr Rosenblatt is the Dean of Tufts University School of Medicine, Boston, Massachusetts. He was previously Professor of Medicine at Harvard Medical School and has served in senior research positions at the Beth Israel Deaconess Medical Center in Boston. He was the founding director of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center.
In addition, Dr Rosenblatt has served as Director of the Harvard-MIT Division of Health Sciences and Technology and as Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed a worldwide development team as well as directing drug discovery efforts in the United States, Japan and Italy. In Japan he was responsible for Merck's clinical research and development; he also headed Merck Research's worldwide University and Industry Relations Department.
Earlier in his career, Dr Rosenblatt was Chief of the Endocrine Unit at Massachusetts General Hospital. He is a graduate of Columbia University and gained his medical qualification at Harvard Medical School.
Dr James Cavanaugh, Chairman of Shire commented:
"We are honored to welcome Dr Rosenblatt to the Board of Directors. His
impressive medical background and research experience will be of great
value as we continue to grow our business through acquisition and product
development. As Shire grows its biopharmaceutical portfolio and expands
'/>"/>
| SOURCE Shire PLC Copyright©2008 PR Newswire. All rights reserved |